AEON Biopharma, Inc. Class A (AEON)

AEON's stock price has significantly declined over the past six months. A public offering in January 2025 led to a 66% stock price crash. In May 2025, NYSE American accepted AEON Biopharma's plan to regain listing compliance. Shareholders have experienced substantial dilution in the past year. In October and November 2025, the company received positive news regarding its interactions with the FDA concerning ABP-450, and H.C. Wainwright maintained a "Buy" rating. AEON Biopharma reported its third-quarter 2025 results in November 2025, including positive ABP-450 biosimilarity data.

No specific information regarding demand seasonality for AEON Biopharma, Inc.'s products and services was found in the provided search results.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 injection, a proprietary botulinum toxin complex, for various medical conditions, particularly in the neurosciences market. The company is focused on therapeutic-only indications for botulinum toxins and is developing ABP-450 as a biosimilar to BOTOX. AEON aims for accelerated U.S. market entry for ABP-450, potentially covering all of BOTOX's approved therapeutic indications under a single FDA approval.

AEON Biopharma, Inc. is headquartered in Irvine, California. The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.

AEON Biopharma's brand reputation has been influenced by its progress in developing ABP-450 and its interactions with regulatory bodies. The company has reported positive biosimilarity results for ABP-450, strengthening confidence in its biosimilar strategy. However, the company faced a significant event in May 2024 when it announced the restatement of previously issued financial statements for periods in 2023 due to an error that resulted in non-cash corrections to increase the reported loss and led to the determination that material weaknesses existed in internal controls as of December 31, 2023.

The ownership structure of AEON Biopharma stock includes institutional, insider, and retail investors. Institutional investors hold approximately 10.03% to 22.78% of the company's stock. Insiders own about 15.58%, while the general public and individual investors hold a significant portion, ranging from 56% to 73.42%. Major institutional shareholders include Dauntless Investment Group, LLC, Vanguard Group Inc, and Geode Capital Management, LLC. Top individual shareholders include Robert Palmisano and Jorey Chernett.